See how #antibody and vaccine approaches for #COVID19 compare and how each is manufactured: https://t.co/t1YQv1suNL pic.twitter.com/5tkIvblrjQ
— Regeneron (@Regeneron) August 20, 2020
We are collaborating with @Roche to significantly increase global supply of Regeneron’s investigational antibody cocktail for #COVID19: https://t.co/A4i6ZZh482 pic.twitter.com/N1lEfTrKmO
— Regeneron (@Regeneron) August 19, 2020
Watch: Drew Murphy, PhD, EVP of Research, explains the #science behind how novel #antibody medicines can emulate the natural disease-fighting process. For more: https://t.co/VtwzW1XHKg pic.twitter.com/9Kd1M934rN
— Regeneron (@Regeneron) August 11, 2020
Congrats to Raquel Deering, PhD, who was named one of @INVIVOnow’s Rising Leaders in Life Sciences for her work using next-gen sequencing methods to “outsmart cancer.” https://t.co/yh52K7DvBt
— Regeneron (@Regeneron) May 13, 2020
#COVID19 program update: We have moved our top SARS-CoV-2-neutralizing antibodies into preclinical- and clinical-scale cell production lines & remain on track to have supply available for clinical studies in June. Read on: https://t.co/w3wjPjXlmB pic.twitter.com/GEcO3ClFVe
— Regeneron (@Regeneron) April 16, 2020
Congrats to our Prez and CEO (& @uvamedalum) Len Schleifer for being recognized with the Walter Reed Distinguished Achievement Award for his leadership and commitment to innovation: https://t.co/FGHkql59Ng pic.twitter.com/TDmiPnqz2u
— Regeneron (@Regeneron) September 25, 2020
During #DPharm2020, David Weinreich, MD, SVP and Head of Global Clinical Development, shared how we are rapidly responding to #COVID19 while maintaining our high-science principles and quality standards. For more: https://t.co/yKKW8dOoY9 pic.twitter.com/4DP5HwDIrB
— Regeneron (@Regeneron) September 25, 2020
We second that! Congrats to @mayaajmera on the @NSF_NSB 2020 Public Service Award for inspiring generations of young people to be #STEM leaders and innovators through her work with @Society4Science: https://t.co/vAhKAaZiSN https://t.co/dvKlcWtXlD
— Regeneron (@Regeneron) September 23, 2020
Regeneron is top 10 on the @fortunemagazine #ChangeTheWorld list for applying our technologies and expertise to diseases like Ebola and COVID-19. See the list and all the orgs that are #DoingWellByDoingGood: https://t.co/7LF3XiiDU8
— Regeneron (@Regeneron) September 21, 2020
Read about our second late-breaking #ESMO20 presentation with @Sanofi featuring pivotal trial data for an investigational #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC): https://t.co/VeJykCRPgp pic.twitter.com/tnG6eZxKQP
— Regeneron (@Regeneron) September 21, 2020
Today at #ESMO20: We shared late-breaking pivotal trial data for an investigational #immunotherapy in locally advanced #BasalCell #Carcinoma (BCC). Read more about our presentation with @Sanofi: https://t.co/ygrvPrHBXY pic.twitter.com/cFifC5z8mB
— Regeneron (@Regeneron) September 18, 2020
Watch: #RegeneronScientist Alina Baum, PhD, shares how #antibodies work to protect the healthy human cells against pathogens. Learn about antibody medicines: https://t.co/msL7mRf6WS pic.twitter.com/Y0Dj7e9P6c
— Regeneron (@Regeneron) September 17, 2020
Uncertainty can have a big impact on people with #AtopicDermatitis and those in their lives. Help us #ChangeAD by submitting your idea at https://t.co/2pzIIgYNIw. https://t.co/JoW12TLs7g
— Regeneron (@Regeneron) September 14, 2020
#Breaking: Our investigational #COVID19 anti-viral antibody cocktail will be evaluated as part of the @UniofOxford Phase 3 RECOVERY trial: https://t.co/nilVh0LZVR pic.twitter.com/swaGGtwQZm
— Regeneron (@Regeneron) September 14, 2020
Announcing with @Sanofi, the FDA has granted Breakthrough Therapy designation for our investigational medicine in #EosinophilicEsophagitis. Learn more: https://t.co/jNAYVGWE2b pic.twitter.com/xylZ3i4Zmz
— Regeneron (@Regeneron) September 14, 2020
We’re sharing new long-term data (up to three years) for our moderate-to-severe #asthma medicine at #ERSCongress. This includes safety and the impact of some of asthma’s most debilitating symptoms. Find out more: https://t.co/sZbJpPdvUB CC: @Sanofi
— Regeneron (@Regeneron) September 8, 2020
From his time playing football, Wilson learned at a young age that even when things are broken, they can be fixed. Watch his story and learn how this lead him to a career in clinical trial development. pic.twitter.com/VehwHTDb0I
— Regeneron (@Regeneron) September 3, 2020
#ESMO20: Announcing the acceptance of late-breaking oral presentations on our pivotal immunotherapy trials in advanced #basalcell #carcinoma (BCC) and advanced #NonSmallCellLungCancer (#NSCLC): https://t.co/7glgFBDvKj CC: @Sanofi pic.twitter.com/kiekMgoaoK
— Regeneron (@Regeneron) September 3, 2020
.@YonkersPartners Regeneron Science Research enables students from the Yonkers school district to participate in an after-school #science research program. Recent graduates of the Regeneron-supported initiative reflect on their experiences: https://t.co/nLHKINRsYc
— Regeneron (@Regeneron) September 2, 2020
Thanks to our colleagues who have volunteered 1.7K+ hours over three years to maintain Westchester County Parks, we’ve been recognized with the Business Impact Award by @FriendsofParks: https://t.co/0tKveSmT87 #ResponsibleRegeneron
— Regeneron (@Regeneron) August 28, 2020
#RegeneronIreland is growing its team by 40% to support the production of our existing life-changing medicines. Learn more: https://t.co/GSypUPXmGs pic.twitter.com/9f1m1ZUG3I
— Regeneron (@Regeneron) August 27, 2020
Doing what’s right has always been core to how we run our business. In April, we announced our 2025 global responsibility goals to help further our efforts. Read more from @halamirza, SVP, Corp Comms & Citizenship: https://t.co/qNVKVL1Nnb #ResponsibleRegeneron
— Regeneron (@Regeneron) August 26, 2020
We have been recognized by @Forbes as one of America’s Best-in-State Employers for another year. Find out more about us: https://t.co/AC6iWsPPA2 pic.twitter.com/PL3csXCcuE
— Regeneron (@Regeneron) August 25, 2020
Today @NEJM published positive Phase 3 results for our investigational medicine in patients with #HoFH, an ultra-rare inherited form of high cholesterol. #FHcommunity #RareDisease More: https://t.co/49keEeIgPx
— Regeneron (@Regeneron) August 19, 2020
At Regeneron, we’re building a more sustainable future. By 2035, our goal is to match 100% of our electricity consumption with electricity from certified renewable energy sources.⚡ Read more: https://t.co/PXmKYebc1O #ResponsibleRegeneron pic.twitter.com/xo7LnxbwMK
— Regeneron (@Regeneron) August 14, 2020
Thanks to all who submitted a proposal to the 2019 ‘Agents of Change’ AD Challenge. Your ideas will help us support the #AtopicDermatitis community. Learn about the initiative and grant recipients at https://t.co/obIdYb9cT1 pic.twitter.com/gypordlWIU
— Regeneron (@Regeneron) August 7, 2020
For the second consecutive year, we have been named as one of @FastCompany's 2020 Best Workplaces for Innovators. Learn how we foster a collaborative culture driven by #science: https://t.co/UMGQRAs2TM #FCBestWorkplaces pic.twitter.com/E56AIguWsc
— Regeneron (@Regeneron) July 29, 2020
#Ebola update: @BARDA has procured our investigational Ebola cocktail treatment for national preparedness. Learn more: https://t.co/ZMxtV3LQne
— Regeneron (@Regeneron) July 29, 2020
Watch: #STEM influencer @FascinateSci recently spoke with Alina Baum, PhD, of our infectious diseases team about our approach to researching potential #antibody medicines for #COVID19 and what it’s like being a scientist during the pandemic: https://t.co/jTkQGokcTr
— Regeneron (@Regeneron) July 22, 2020
The #RGC is partnering with @Ancestry to advance current understanding of #COVID19 susceptibility, severity and outcomes. For more on this new collaboration: https://t.co/5uzYgGlCOw
— Regeneron (@Regeneron) July 15, 2020
https://twitter.com/Regeneron/status/1283064845491937282
Regeneron immunology expert, Jamie Orengo, PhD, sees firsthand the impact #asthma and #allergies have on everyday life. Learn how her team is exploring the use of #antibody medicines for allergic diseases: https://t.co/msL7mRf6WS pic.twitter.com/UzMxyv9jYm
— Regeneron (@Regeneron) July 13, 2020
Announcing large-scale manufacturing & supply agreement of our investigational #COVID19 medicine for @BARDA & @JPEOCBRND @DeptofDefense: https://t.co/b1YYy8P0Sq
— Regeneron (@Regeneron) July 7, 2020
We have initiated a Phase 3 prevention trial for our investigational #COVID19 dual-antibody medicine in collaboration with @NIAIDNews (a part of @NIH). Read more: https://t.co/4GkTXzDRMM pic.twitter.com/DAYjFIPhzl
— Regeneron (@Regeneron) July 6, 2020
Together with @Sanofi we’ve provided an update from our Phase 3 U.S. clinical trial for #COVID19 patients with our IL-6 receptor antibody. Learn more: https://t.co/ckHhKkEahw
— Regeneron (@Regeneron) July 2, 2020
Last year, nearly 60% of our colleagues worldwide volunteered their time to local non-profit organizations. Learn how we support our communities through programs such as #RegeneronD4DG, in our 2019 Responsibility Report: https://t.co/Z9NblB6qzq pic.twitter.com/ewdc5XVDkg
— Regeneron (@Regeneron) June 24, 2020
Congrats to the recipients of the eighth annual Regeneron Prize for Creative Innovation, which celebrates and rewards cutting-edge thinking from the next generation of young #scientists. Read about their winning proposals here: https://t.co/8iABqWz64Q pic.twitter.com/RkxkkNLamI
— Regeneron (@Regeneron) June 22, 2020
The FDA has approved a new option for administering one of our medicines. Find out how this innovation can help patients: https://t.co/CnM6lkD4t1 pic.twitter.com/XPgbrAxjgQ
— Regeneron (@Regeneron) June 19, 2020
The second defines the protective value of a multiple-#antibody approach against #SARSCoV2 ‘viral escape’ mutations: https://t.co/anSXRfg92V via @ScienceMagazine
— Regeneron (@Regeneron) June 15, 2020
Today, we’re announcing @ScienceMagazine will publish two manuscripts which highlight the potential of our investigational anti-viral antibody cocktail to protect against #SARSCoV2 ‘viral escape’ mutations: https://t.co/boN2i5OF8S pic.twitter.com/bYDVtps4Nn
— Regeneron (@Regeneron) June 11, 2020
Today, we announce the initiation of clinical trials for our investigational anti-viral antibody cocktail for the treatment and prevention of COVID-19: https://t.co/PetA4EsQGf pic.twitter.com/ba1wDlJEUu
— Regeneron (@Regeneron) June 11, 2020
Yesterday at #BIODigital, our President and CSO, George Yancopoulos, discussed the importance of a united effort amongst our biopharma peers in the fight against #COVID19. Learn about our COVID-19 response efforts: https://t.co/h2dc05EGF0 https://t.co/HZyFtn4if2
— Regeneron (@Regeneron) June 9, 2020
Regeneron & @IntelliaTweets expand collaboration to develop CRISPR/Cas9-based treatments: https://t.co/HsJpVdyvPB
— Regeneron (@Regeneron) June 1, 2020
Check out our latest #immunooncology research in advanced #NonMelanoma #SkinCancer (NMSC) with @Sanofi, including results from the largest and most mature prospective dataset in advanced Cutaneous #SquamousCellCarcinoma (CSCC). #ASCO20
— Regeneron (@Regeneron) May 29, 2020
Announcing with @Sanofi at #ASCO20: longer-term outcomes and first post-hoc quality-of-life results from our pivotal Phase 2 trial in advanced Cutaneous #SquamousCellCarcinoma (CSCC). Learn more: https://t.co/1zQIvrGMQQ pic.twitter.com/0SVo3rDdgm
— Regeneron (@Regeneron) May 29, 2020
Our growing #RegeneronIreland team at our IOPS site in Limerick is officially 1,000 people strong! In six years, they’ve built the largest biologics production facility in Ireland and formed a strong community. Learn more about our growing team: https://t.co/u7xBR2Ilod pic.twitter.com/lMSU87JmMK
— Regeneron (@Regeneron) May 27, 2020
Our newly published research with @DukeU provides an atlas of the cells that regulate eye pressure — crucial information that may lead to future #glaucoma treatments approaches. #DYK there are 12 cells types in a space about half as thick as a penny? https://t.co/0dQj1XK8Xz pic.twitter.com/3ZXEF1f7RN
— Regeneron (@Regeneron) May 26, 2020
The FDA has approved our medicine for children aged 6-11 years with uncontrolled moderate-to-severe #AtopicDermatitis. Read more: https://t.co/9IEHlTHY8y CC: @Sanofi pic.twitter.com/KFTA2qA0rX
— Regeneron (@Regeneron) May 26, 2020
With @Sanofi, we are announcing positive results from our trial in adults and adolescents with #EosinophilicEsophagitis. Read more: https://t.co/lS0FMYybsA
— Regeneron (@Regeneron) May 22, 2020
Yesterday at #RegeneronISEF, Regeneron infectious disease experts, Christos Kyratsous, Leah Lipsich and Serge Monpoeho, shared a behind-the-scenes look at our efforts to combat #COVID19. For more about our efforts: https://t.co/QZZc3YBBeZ CC: @Society4Science https://t.co/qqhH5FWQsc
— Regeneron (@Regeneron) May 20, 2020
Our Prez & CEO Len Schleifer sat down with @MegTirrell during @CNBC’s #HealthyReturns virtual event to discuss how we’re applying our core technologies to fight infectious diseases like #COVID19. https://t.co/rAxLeXyolb
— Regeneron (@Regeneron) May 15, 2020
In partnership with the Colorado Center for Personalized Medicine at @CUAnschutz, the #RGC will sequence 450,000 DNA samples from patients at @uchealth. Read more about how we're advancing the field of #genetics and precision medicine: https://t.co/5hG8FNf4TW pic.twitter.com/q6mGg5gmP8
— Regeneron (@Regeneron) May 11, 2020
Facing unprecedented health crises, our team has responded with urgency, applying our core technologies to fight infectious diseases. To learn more about our efforts, read our 2019 Annual Report: https://t.co/2yBJUeBkEU pic.twitter.com/VqZkwWeS6k
— Regeneron (@Regeneron) May 8, 2020
We are joining the @AmDiabetesAssn to focus on an often-overlooked complication for the 30m+ American adults living with #diabetes: eye disease. Stay tuned for more on how we plan to help raise awareness. More: https://t.co/O19L7Rfpnf pic.twitter.com/l3OoBPyBKV
— Regeneron (@Regeneron) May 6, 2020
With @Sanofi, we're announcing clinically meaningful results from a pivotal Phase 2 clinical trial for our #immunotherapy in advanced #basalcell #carcinoma (BCC). Learn more: https://t.co/dFCrEbLuai
— Regeneron (@Regeneron) May 5, 2020
We continue to tap into our collective expertise, technology and resources to do what's right. Hala Mirza, SVP, Corp Comms & Citizenship, introduces our new global responsibility goals in our latest #RegeneronPerspectives blog:
— Regeneron (@Regeneron) April 27, 2020
With @Sanofi, we're announcing the pivotal Phase 3 trial for our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) was stopped early due to highly significant results. https://t.co/8duu67iYPY
— Regeneron (@Regeneron) April 27, 2020
Regeneron and @Sanofi provide update on U.S. Phase 2/3 trial of repurposed IL-6 inhibitor medicine (currently approved for rheumatoid arthritis) in hospitalized COVID-19 patients https://t.co/8KAZob0Nfd pic.twitter.com/ZuyQ4DFqfd
— Regeneron (@Regeneron) April 27, 2020
At Regeneron, we are committed to following the #science to help people with serious diseases. Today on FOP Awareness Day learn how we apply our technologies and novel approaches to investigate #rarediseases like fibrodysplasia ossificans progressiva.
— Regeneron (@Regeneron) April 23, 2020
The PALM clinical trial is the recipient of @SCTorg’s David Sackett Trial of the Year Award, recognizing the amazing collaboration behind this important study. We’re currently applying lessons from our #Ebola research and development to find a potential medicine for #COVID19.
— Regeneron (@Regeneron) April 22, 2020
FDA accepts the biologics license application for our investigational antibody medicine for Ebola: https://t.co/I3UkEXEfcy
— Regeneron (@Regeneron) April 16, 2020
Announcing a new collaboration with Zai Lab for our investigational bispecific antibody for B-cell non-Hodgkin #lymphoma. Read more: https://t.co/LEtydrJisb
— Regeneron (@Regeneron) April 8, 2020
Join us by supporting @CommFound518’s Capital Region Community Response Fund to help rapidly deploy resources to community-based organizations at the front lines of the #COVID19 outbreak: https://t.co/WkQW3hIDiV
— Regeneron (@Regeneron) April 7, 2020
New announcement on our @Sanofi restructuring and changes in Regeneron’s accounting presentation. Read more: https://t.co/0NBVMuPlbu
— Regeneron (@Regeneron) April 6, 2020
Read the latest #RegeneronPerspectives blog for more from #RegeneronIOPS leadership: https://t.co/85IRZc5XoB
— Regeneron (@Regeneron) April 1, 2020
We’ve treated the first ex-US severe #COVID19 patient in our global clinical program w/ @Sanofi with our IL-6 receptor antibody. Learn more: https://t.co/srR5JmlJN1
— Regeneron (@Regeneron) March 30, 2020
Our CSO George Yancopoulos discussed on @CNNi how we’re applying lessons from our #Ebola research to finding a potential medicine for #COVID19. Watch via w/ @jchatterleyCNN https://t.co/98CZw8bBRy
— Regeneron (@Regeneron) March 27, 2020
Healthcare workers at the front lines of the #COVID19 pandemic critically need medical supplies. We’re supporting @AfyaFoundation’s efforts to get supplies to NY-based qualified health centers. Learn more: https://t.co/UVKcTlmxCo
— Regeneron (@Regeneron) March 18, 2020
Update on our #COVID19 novel antibody program: We’ve identified hundreds of virus-neutralizing antibodies from our VelocImmune technology and are now selecting the top candidates for clinical testing. Learn more: https://t.co/JhkedKl8yM
— Regeneron (@Regeneron) March 17, 2020
If you or someone you know is sick, call your doctor and visit this resource from @CDCgov for more info: https://t.co/cYReu4Y7vz
— Regeneron (@Regeneron) March 16, 2020
We’ve initiated a global clinical program w/ @Sanofi for people hospitalized with severe #COVID19, testing our IL-6 receptor antibody. Read on: https://t.co/uKmBRgSBf3
— Regeneron (@Regeneron) March 16, 2020
It’s #ExomeDay! #ICYMI: The #RGC has sequenced one million exomes, making it the largest database of its kind. Learn more about this genomic research initiative:
— Regeneron (@Regeneron) March 11, 2020
We shared our current timeline for COVID-19 drug discovery/development yesterday at #CowenHealthCare and the White House: pic.twitter.com/pa1PCpyKTz
— Regeneron (@Regeneron) March 3, 2020
We are excited to join communities around the world to recognize #RareDiseaseDay. At Regeneron, we are on a journey to understand the #science behind these serious diseases to develop meaningful medicines. Learn why this day is so important: https://t.co/cmVZeQpCSs
— Regeneron (@Regeneron) February 29, 2020
We're proud to support this important legislation & the leadership of @NYGov in fighting intolerance, ignorance & hate. https://t.co/I9r0543cBZ
— Regeneron (@Regeneron) February 27, 2020
Thanks to our dedicated colleagues, for another year we’ve been recognized on @FortuneMagazine and @GPTW_US's list of #100BestCos! #GreatPlaceToWork https://t.co/PiLtMdVBNO
— Regeneron (@Regeneron) February 18, 2020
We’re committed to celebrating these hard-working students in the manner they deserve, and look forward to meeting them in person later this year when they will compete, receive prizes and share their important research with the public. #RegeneronSTS https://t.co/nWqffTLVeY
— Regeneron (@Regeneron) March 3, 2020
.@Society4Science recently announced the recipients of this year’s STEM Action Grant Program. This Regeneron-supported initiative provides funding to organizations working to increase participation of underrepresented and underserved populations in #STEM fields. Learn more: https://t.co/Pua34Yp2VO
— Regeneron (@Regeneron) July 8, 2020
For the first time in the competition's history, the @Regeneron Science Talent Search went virtual this year. Relive some of the amazing memories! #RegeneronSTS pic.twitter.com/88EfzXZO39
— Society for Science (@Society4Science) September 1, 2020
For the first time in its 79-year history, the Science Talent Search went virtual. Read more about how we did it in @sciam. via @SchamandaBaker #RegeneronSTS https://t.co/q8oiSeuju6
— Society for Science (@Society4Science) August 19, 2020
We're grateful for our #SSPalumni who are leading & tackling the most urgent scientific & humanitarian crisis of our time. See what George Yancopoulos, Len Schleifer & the @Regeneron team are doing & why we're so proud to partner with these leaders in #STEM! #COVID19 pic.twitter.com/QQKZEGK2rV
— Society for Science (@Society4Science) May 1, 2020
As companies race to find treatments and vaccines for coronavirus, @JNJNews’s Paul Stoffels and @Regeneron’s George Yancopoulos join @GStephanopoulos to give the latest on their research. See it on @ThisWeekABC https://t.co/sRvHtXTwAz pic.twitter.com/RyIhRqimdH
— This Week (@ThisWeekABC) May 9, 2020
It's all-hands-on-deck at pharmaceutical companies around the world as the coronavirus spreads. I visited Regeneron, a company that's racing to develop a drug and has been successful in the past at treating Ebola. https://t.co/uHBRkmkIfU
— Lester Holt (@LesterHoltNBC) March 10, 2020
We are proud to partner with @Regeneron to develop a potential therapeutic needed to #SaveLives from #COVID19. BARDA is supporting the Phase 2/3 clinical trial for this product. https://t.co/IweZ9P3DnB pic.twitter.com/e684tTf27I
— BARDA (@BARDA) March 22, 2020
https://twitter.com/GPTW_Ireland/status/1232796927797932034